secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001615219-24-000045
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharmaceuticals effects 1-for-8 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split effective 5:00 p.m. ET on June 14, 2024; trading on split-adjusted basis begins June 17.
- Shares outstanding reduced from ~4.7 million to ~0.6 million; new CUSIP 79400X404.
- Fractional shares paid in cash based on closing price on effective date; ticker SLRX unchanged.
- Split intended to meet Nasdaq $1.00 minimum bid price requirement; stockholders had approved ratio range 1:4 to 1:8.
- Authorized shares and par value unaffected; options and warrants adjusted proportionally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000045/0001615219-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000045/flks-20240614.htm
  HTML page:      https://secwatch.observer/filing/0001615219-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer